(Q45187063)

English

The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study

scientific article published on 14 December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Flendrie M

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Creemers MC

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Welsing PM

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

van Riel PL

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

publication date

14 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

472-478

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

The epidemiology of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Clinical pharmacokinetics of leflunomide

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH508

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KEH508

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45187063&oldid=2153565026"